Drug Trial Radar · NCT02027701
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Jul 30, 2014
Primary completion
Jul 10, 2017
Study completion Jul 10, 2017
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an extension study to the pivotal study IgPro20\_3003 (NCT01545076). The purpose of this extension study is to investigate the long-term treatment of CIDP with IgPro20, with regard to safety and efficacy. Subjects who have completed subcutaneous (SC) Week 25 or were successfully rescued from a CIDP relapse during the SC Treatment Period of pivotal study IgPro20\_3003 (NCT01545076) will have the option to receive open-label low-dose IgPro20 (0.2 g/kg bodyweight \[bw\]) weekly for up to 48 weeks. Subjects relapsing on low-dose IgPro20 will either return to high-dose IgPro20 (0.4 g/kg) immediately or be discontinued, depending on investigator's judgment. Subjects returning to high-dose IgPro20 will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment. If subjects do not successfully recover from CIDP relapse within 4 weeks, they will be withdrawn. The treatment duration will be up to 48 weeks, followed by a completion visit (week 49).
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
IgPro20Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs) Per InfusionTime frame: Up to 49 weeks
Locations
33 sites in 11 countries. Site status is shown where the registry gives one.
Site Reference 8400181
Birmingham, Alabama
Site Reference 8400167
Los Angeles, California
Site Reference 8400166
Kansas City, Kansas
Site Reference 8400169
New York, New York
Site Reference 8400182
Charlotte, North Carolina
Site Reference 0360017
Woolloongabba, Queensland, Australia
Site Reference 0360011
Fitzroy, Victoria, Australia
Site Reference 1240009
Toronto, Ontario, Canada
Site Reference 1240007
Greenfield Park, Quebec, Canada
Site Reference 2030009
Hradec Králové, Czechia
Site Reference 2030002
Hradec Králové, Czechia
Site Reference 2500022
Nice, France
Site Reference 2760069
Berlin, Germany
Site Reference 2760072
Berlin, Germany
Site Reference 2760049
Bochum, Germany
Site Reference 2760094
Essen, Germany
Site Reference 2760054
Hanover, Germany
Site Reference 2760055
Leipzig, Germany
Site Reference 2760047
Potsdam, Germany
Site Reference 2760039
Würzburg, Germany
Site Reference 2760052
Essen, North Rhine-Westphalia, Germany
Site Reference 3800031
Milan, Italy
Site Reference 3920038
Chiba, Japan
Site Reference 3920061
Kanagawa, Japan
Site Reference 3920040
Nagoya, Japan
Site Reference 3920065
Tokyo, Japan
Site Reference 3920037
Tokorozawa, Saitama, Japan
Site Reference 3920035
Ube, Yamaguchi, Japan
Site Reference 5280001
Amsterdam, Netherlands
Site Reference 7240011
Barcelona, Spain
Site Reference 7240010
Barcelona, Spain
Site Reference 8260019
London, United Kingdom
Site Reference 8260032
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.